Treatment for multiple sclerosis (MS) is an evolving area and one in which new therapeutic approaches are rapidly advancing. Led by Dr. Saud Sadiq, the Tisch MS Research Center of New York is pursuing a Phase II clinical trial exploring the use of stem cell technology for the treatment for MS. The announcement followed positive results from an FDA-approved Phase I stem cell trial for MS. [Read more…]
BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.
Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19
With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.
Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).
In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]
Nucleus Biologics, Enabling Reproducible Science with David Sheehan (CEO)
In this interview with David Sheehan (CEO), we explore how Nucleus Biologics is revolutionizing the cell culture market through a concept known as “Precision Cell Culture.” The focus of Nucleus Biologics is to deliver superior cell culture products by leveraging a transparent, consistent and proven supply chain that eliminates variability for its customers. In addition to its novel Physiologix™ product line, Nucleus Biologics provides the highest quality Australia and New Zealand origin fetal bovine serum (FBS) available in the market with a goal to enable better lifesaving science.
With an estimated $28 billion lost per year to irreproducible biology research, it is clear that the market is overdue for disruption and Nucleus Biologics appears to be the company positioned to do it. In this interview, we explore Mr. Sheehan’s background, the disruptive nature of Nucleus Biologics, and his inspiring vision for the future. [Read more…]
Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics
Fujifilm Cellular Dynamics is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.
The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
Stemmatters, a Portuguese Integrated Therapeutics Developer and Cell Therapy CDMO
Stemmatters is a Portuguese contract development and manufacturing (CDMO) organisation based in Barco, Guimarães. Originally a spin-off from University of Minho, it offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices.
In the interview below, we explore Stemmatters history, services, manufacturing facilities, and future goals. Enjoy! [Read more…]
